2008/11/3
「いよいよ殺人ワクチンで人口削減開始」
Rumsfeld:Why not another 9.11
http://www.whatreallyhappened.com/
In a newly-released tape of a 2006 neocon luncheon meeting featuring former War Secretary Donald Rumsfeld, attended by ex-military "message force multiplier" propaganda shills Lt. General Michael DeLong, David L. Grange, Donald W. Sheppard, James Marks, Rick Francona, Wayne Downing, Robert H. Scales and others, Rumsfeld declared that the American people lack "the maturity to recognize the seriousness of the 'threats'" -- and need another 9/11.
Posted May 18, 2008 02:08 PM PST
Category: 911
, Category: COVER-UP/DECEPTIONS
Lake Placidに世界の制服組が集合し何やら不穏な動きが?
http://web.archive.org/web/20070518002941/http://www.pgs.ca/index.php/Iraq/252
Rebuilding America's Defences:Strategy,Forces and Resources for a New Century (1992年発行)
The U.S must remain in the forefront of all research relating to the "art of warfare"including"the world of microbes"(advanced forms of biological warfare that can "TARGET"specific genotypes may transform biological warfare from the realm of terror to a politically usefull tool。(要約:人種別に効果のある,生物兵器は便利な政治的な道具となる。戦争と言う芸術の名のもとに)。
これが,西ナイル熱,炭ソ菌,鳥インフルエンザ,エイズ菌,そしてタミフルの策略。世界人口の三分の二皆殺し計画の実行案である。これはけっしておふざけでも,冗談でもない。
Further,the process of transformation,even if it brings revolutionary changes,is likely to be a long one,absent some catastrophic and catalyzing event -like a new pearl Harbor。(要約:何よりも確たるものにするには,パール・ハーバーのような新たな悲劇的・壊滅的な仕掛けが求められる)。
Virus Flow Chartは管理人が翻訳したもので医学用語には間違いがあるかもしれないのでその点はご容赦願いたい。すでに数千人の医師にワクチン投与がされ自殺したり妊産婦を拒否するなど病院全体で異常行動が出ている。
拙稿:Blue Print for PNC参照
BOYD E.GRAVES氏のHPー必見
厚生省は731部隊の末裔である。 731とはフリーメーソンでドアを7.3.1と二回叩くのが合図となっている。
731部隊はガーター騎士団である天皇の部隊である。上は731部隊本部棟。日本人はある意味で世界一残忍な民族かもしれない。しかも魑魅魍魎で自分に危険が迫るとすぐカモフラージュしてしまう。
江戸伊勢屋治助著『百鬼夜講化物語』。向かって右が魑魅、左が魍魎。
731細菌部隊の全貌参照
天皇家もう一つの紋章
魂を売る位なら死んだ方がいい。死ぬ位なら魂を売った方がいい。この三人は後者を選んだ。
統一協会に賛辞を送る人たち参照
ラムズフェルドが会長を務めていたギリアド
原文
日本政府は、鳥インフルエンザ問題が喧伝されて以来、タミフル備蓄を急いできた。また、日本政府はアジア諸国のタミフル備蓄支援に積極的に動いてきた。2005年12月12日には、小泉首相(当時)が、ASEANプラス3首脳会議において、アジア地域で50万人分のタミフル備蓄を支援する方針を示している。
この間、「幻視」、「譫妄=精神的興奮を伴う意識の混濁」、「幻覚」、「意識レベルの低下」、「けいれん」といった異常行動とタミフルとの因果関係が指摘されてきたが、政府の対応は何故か鈍かった。ようやく2007年3月23日、柳沢厚労相は、タミフルと異常行動との因果関係に「否定的」としてきた従来の判断で良かったのかを、見直しをしなくてはいけないと語るに至った(→タミフル服用後の異常行動についてここをクリック)。
タミフルは、スイスの医薬品大手ロシェ社が製造販売しているが、その特許を所有しているのは、カリフォルニア州に本拠を構えるバイオテック企業ギリアド・サイエンシズ(Gilead Sciences)である。『日本証券新聞』は、ギリアドについて次のように書いていた。「薬品大手で、バイオテロ対策関連企業でもある。米国防長官のドナルド・ラムズフェルド(Donald Rumsfeld)氏は、2001年まで当社の会長だった。抗ウイルス性物質、抗真菌物質、抗細菌など抗感染薬の研究および臨床試験に尽力。主要薬品は『バイリード』(HIV 治療薬)、『アムビソーム』(抗菌剤)など。藤沢薬品との提携により『アムビソーム』を米国内で共同販売。スイスのロシュ社と共同開発したインフルエンザ治療薬の『タミフル』については、わが国においてロシュ社の子会社となった中外製薬が販売」(『日本証券新聞』2004年5月24日付)。
CNNの報道によると、ラムズフェルドは1997年から2001年まで、ギリアドの会長を務め(同社リリース)、その後も同社の株を保有していた。さらに、ジョージ・シュルツ元国務長官もギリアド役員を務め、2005年度に入ってから同社の株700万ドル分を売却している(→関連ブログをクリック)。
タミフルと異常行動は携帯電話の電磁波が関係ある。
Rumsfeld's growing stake in Tamiflu
Defense Secretary, ex-chairman of flu treatment rights holder, sees portfolio value growing.
October 31, 2005: 10:55 AM EST(CNNより)
By Nelson D. Schwartz, Fortune senior writer
NEW YORK (Fortune) - The prospect of a bird flu outbreak may be panicking people around the globe, but it's proving to be very good news for Defense Secretary Donald Rumsfeld and other politically connected investors in Gilead Sciences, the California biotech company that owns the rights to Tamiflu, the influenza remedy that's now the most-sought after drug in the world.
Rumsfeld served as Gilead(株価はここをクリック) (Research)'s chairman from 1997 until he joined the Bush administration in 2001, and he still holds a Gilead stake valued at between $5 million and $25 million, according to federal financial disclosures filed by Rumsfeld.
The forms don't reveal the exact number of shares Rumsfeld owns, but in the past six months fears of a pandemic and the ensuing scramble for Tamiflu have sent Gilead's stock from $35 to $47. That's made the Pentagon chief, already one of the wealthiest members of the Bush cabinet, at least $1 million richer.
Rumsfeld isn't the only political heavyweight benefiting from demand for Tamiflu, which is manufactured and marketed by Swiss pharma giant Roche. (Gilead receives a royalty from Roche equaling about 10% of sales.) Former Secretary of State George Shultz, who is on Gilead's board, has sold more than $7 million worth of Gilead since the beginning of 2005.
Another board member is the wife of former California Gov. Pete Wilson.
"I don't know of any biotech company that's so politically well-connected," says analyst Andrew McDonald of Think Equity Partners in San Francisco.
What's more, the federal government is emerging as one of the world's biggest customers for Tamiflu. In July, the Pentagon ordered $58 million worth of the treatment for U.S. troops around the world, and Congress is considering a multi-billion dollar purchase. Roche expects 2005 sales for Tamiflu to be about $1 billion, compared with $258 million in 2004.
Rumsfeld recused himself from any decisions involving Gilead when he left Gilead and became Secretary of Defense in early 2001. And late last month, notes a senior Pentagon official, Rumsfeld went even further and had the Pentagon's general counsel issue additional instructions outlining what he could and could not be involved in if there were an avian flu pandemic and the Pentagon had to respond.
As the flu issue heated up early this year, according to the Pentagon official, Rumsfeld considered unloading his entire Gilead stake and sought the advice of the Department of Justice, the SEC and the federal Office of Government Ethics.
Those agencies didn't offer an opinion so Rumsfeld consulted a private securities lawyer, who advised him that it was safer to hold on to the stock and be quite public about his recusal rather than sell and run the risk of being accused of trading on insider information, something Rumsfeld doesn't believe he possesses. So he's keeping his shares for the time being.
鳥インフルエンザ大流行の予測は世界の人々をパニックに陥れているが、ギリアド・サイエンシズ社の株を所有するラムズフェルド国防長官やその他政界関係者にとっては朗報だ。
カリフォルニア州に本拠を構えるバイオテック企業ギリアド社は、インフルエンザ治療薬として現在世界中から注目されている『タミフル』の特許を所有している。
1997年からブッシュ政権入閣までの2001年の間、ラムズフェルド国防長官はギリアド社の会長を務めており、現在でも同社の株を保有しているが、その評価額は500万ドルから2,500万ドルの間であることが、ラムズフェルド氏自身による連邦資産公開申告書で明らかになった。
申告書ではラムズフェルド氏が所有する株数の詳細は明らかになっていないが、過去6ヶ月間における鳥インフルエンザ大流行の懸念とタミフル争奪戦の予測により、ギリアド社の株価は35ドルから47ドルに急騰。これにより、すでにブッシュ政権内で最高額の資産を持つ国防長官は、少なくとも100万ドル以上資産を増やしたことになる。
スイスの医薬品大手ロシェ社が製造販売しているタミフル(ギリアド社は販売額の10%のロイヤリティーを受け取っている)で利益を得た政界有力者はラムズフェルドだけではない。
ジョージ・シュルツ元国務長官はギリアド社役員として、2005年度に入ってから同社の株700万ドル分を売却している。
他にも、前カリフォルニア州知事の妻ピート・ウィルソンがギリアド社の役員に就任している。
「政界とこれほど繋がりの深いバイオ企業は他に類を見ない」サンフランシスコのシンク・イクイティ・パートナーズ社アナリストのアンドリュー・マクドナルド氏は評している。
さらに重要なことは、合衆国政府が世界最大のタミフル購入者であるという事実だ。今年7月には、米国防総省は兵士への配給用に、5,800万ドル分のタミフルを注文しており、議会も数十億ドル分の購入を検討中である。2005年度におけるロシェ社のタミフル売り上げ予測額はおよそ10億ドルで、前年度は2億5,800万ドルであった。
タミフルと国家備蓄参照
Donald H. Rumsfeld Named Chairman of Gilead Sciences
Foster City, CA -- January 3, 1997
Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. Dr. Riordan will continue to serve as a director on the board.
"Gilead is fortunate to have had Don Rumsfeld as a stalwart board member since the company's earliest days, and we are very pleased that he has accepted the Chairmanship," Dr. Riordan said. "He has played an important role in helping to build and steer the company. His broad experience in leadership positions in both industry and government will serve us well as Gilead continues to build its commercial presence."
"In my years with Gilead, I have witnessed the evolution of one of the industry's premier biotechnology companies," Mr. Rumsfeld said. "Michael Riordan's founding vision and enormous accomplishments are evident in the VISTIDE® product approval, deep pipeline and talented team that will continue to move Gilead to develop novel treatments for viral diseases."
Mr. Rumsfeld, who joined Gilead as a director in 1988, is currently in private business and is distinguished for his accomplishments in both industry and government. Mr. Rumsfeld served as chief executive officer of G.D. Searle, a worldwide pharmaceutical company, from 1977 to 1985. During this time, his stewardship of Searle earned him awards as the Outstanding Chief Executive Officer in the pharmaceutical industry in 1980 and 1981. He also served as chairman and chief executive of General Instrument Corporation, a diversified electronics company and world leader in broadband and all digital high definition television technology.
A graduate of Princeton University, Mr. Rumsfeld has served in numerous positions of public service, including four terms in the U.S. Congress, U.S. Ambassador to NATO, White House Chief of Staff and as the 13th Secretary of Defense. In 1977, Mr. Rumsfeld was awarded the nation's highest civilian award, the Presidential Medal of Freedom.
In addition to Gilead, Mr. Rumsfeld presently serves as an advisor to several companies and as a member of the board of directors of ABB AB; Gulfstream Aerospace Corp.; Kellogg; Metricom, Inc.; Sears, Roebuck and Co. and Tribune Company. Mr. Rumsfeld's current civic activities include service on the board of trustees of the Eisenhower Exchange Fellowship, Freedom House and the RAND Corporation.
Dr. Riordan will continue to assist the company with strategic direction through his involvement on the board of directors. Since founding the company in 1987, Riordan has overseen Gilead's evolution to a leading biotechnology company with its first approved product and a diversified pipeline of antiviral therapies.
"Michael Riordan's vision and leadership have guided Gilead from a start-up to a commercial company, and we are pleased to rely on his continued counsel as an active board member," John C. Martin, Ph.D., President and Chief Executive Officer of Gilead said. "Over the past several years, I have enjoyed working with Don Rumsfeld as an active director and look forward to his new role as Chairman as we continue to build the Gilead business."
Gilead Sciences is a leader in the discovery and development of a new class of human therapeutics based on nucleotides, the building blocks of DNA and RNA. In 1996, Gilead's first product, VISTIDE (cidofovir injection), was cleared by the U.S. Food & Drug Administration for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Gilead has other nucleotide product candidates in human testing for the potential treatment of viral diseases caused by CMV, human immunodeficiency virus (HIV), hepatitis B virus, herpes simplex virus and human papillomavirus.
The Company's research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and genetic code blockers for cancer and other diseases. Gilead's expertise in each of these areas has also resulted in the discovery and development of non-nucleotide product candidates, including neuraminidase inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV.
Press Releases Gilead Science
※投稿されたコメントは管理人の承認後反映されます。
コメントは新しいものから表示されます。
コメント本文中とURL欄にURLを記入すると、自動的にリンクされます。